Price
$56.56-12.00%Social Signal Score
Analyst Ratings
33 analystsRevenue
$267.95M+141.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brett Monia
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,480
- Beta
- 0.42
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.98
Financials
Revenue
$267.95M+141.6%Net Income
$-114.65M-1659.6%EBITDA
$-105.33M-643.8%Free Cash Flow
$549.45M+2494.6%EPS (diluted)
$-0.69-1250.0%Shares Outstanding (diluted)
165.42M+34.1%Operating Expenses
$367.50MCash & Debt
$2.05BReturn of Capital
$0.00Revenue by Segment (annual)
$836.69MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $944.00M | $-381.00M | $-2.38 |
| 2024 | $705.14M | $-453.90M | $-3.04 |
| 2023 | $787.65M | $-366.29M | $-2.56 |
| 2022 | $587.37M | $-269.72M | $-1.90 |
| 2021 | $810.46M | $-28.60M | $-0.20 |
| 2020 | $729.26M | $-444.26M | $-3.18 |
| 2019 | $1.12B | $278.14M | $2.10 |
| 2018 | $599.67M | $273.74M | $2.07 |
| 2017 | $514.18M | $346.0K | $0.15 |
| 2016 | $372.78M | $-60.40M | $-0.72 |
| 2015 | $283.70M | $-88.28M | $-0.74 |
| 2014 | $214.16M | $-38.98M | $-0.33 |
| 2013 | $147.28M | $-60.64M | $-0.55 |
| 2012 | $102.05M | $-65.48M | $-0.65 |
Valuation
IONShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10Social Signal Score
Mentions (23)
- News (RSS)investing·13d ago·Negative
Ionis, Roche report positive phase 3 data for kidney drug
View source ↗ - News (RSS)fool·15d ago·Neutral
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook Shares of Ionis are down more than 40% so far this year.
View source ↗ - Newsfool.com·16d ago·Neutral
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder.
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks Ionis Pharmaceuticals NASDAQ: IONS CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)finance.yahoo.com·22d ago·Negative
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. Pelacarsen was initially discovered by <[+333 characters]
View source ↗ - News (RSS)seekingalpha·25d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsfool.com·26d ago·Neutral
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
View source ↗ - News (RSS)zerohedge·27d ago·Negative
…third quarter and fiscal 2026 results. Herbalife (HLF) rises 7% after the maker of dietary supplements announced a $250 million share buyback. Ionis Pharmaceuticals (IONS) falls 10% and Amgen (AMGN) slumps 5% after Novartis AG said its heart medication, pelacarsen, failed in a final-stage study. Pharvaris (PHVS) soars 25% after a Phase 3 trial of its deucrictibant extended-release tablet for the prevention of hereditary angioedema attacks met its primary and secondary endpoints. Rigetti Computin…
View source ↗ - News (RSS)seekingalpha·28d ago·Neutral
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·28d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow (NASDAQ:IONS) 2026-09-07 Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow (NASDAQ:IONS) 2026-09-07
View source ↗ - News (RSS)yahoo·31d ago·Negative
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
View source ↗ - News (RSS)seekingalpha·31d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
View source ↗ - Newsmarketbeat.com·31d ago·Negative
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
View source ↗ - Newszacks.com·31d ago·Negative
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
View source ↗ - Newsbusinesswire.com·32d ago·Negative
… only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affe…
View source ↗ - Newsreuters.com·32d ago·Neutral
US FDA approves Ionis Pharma's therapy to treat rare brain disorder The U.S. FDA on Thursday approved Ionis Pharmaceuticals' therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorder.
View source ↗ - Newsfool.com·33d ago·Negative
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone Ionis experienced a double-whammy in July with two clinical setbacks. However, those were partnered programs, with Ionis' financial impact cushioned.
View source ↗ - Newsfool.com·45d ago·Positive
Breakfast News: A Conversation With Ionis CEO Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39% year to date -- beating tech and running even with energy.
View source ↗ - Newsfool.com·53d ago·Neutral
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report.
View source ↗ - Newsbusinesswire.com·58d ago·Negative
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-1.00 per share
Typical surprise +36.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.69 vs $-1.09beat
- Wed, Apr 29$-0.56 vs $-0.85beat
- Wed, Feb 25$-1.41 vs $-1.24miss
- Wed, Oct 29$-0.61 vs $-1.15beat
- Wed, Jul 30$0.86 vs $0.27beat
- Wed, Apr 30$-0.75 vs $-1.11beat
Estimates and results for IONS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IONS officers and directors.
- Bought
- $1.1m
- Sold
- $26.6m
2 trades
23 trades
- Hayden Michael Rbought
- Hayden Michael Rbought
- Bennett C Franksold
- Bennett C Franksold
- Diaz Allene M.sold
- Kordasiewicz Holly B.sold
- Klein Joseph Iiisold
- Klein Joseph Iiisold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (355d later)Buy$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Feb 23, 2016 (34d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.